Please use this identifier to cite or link to this item:
http://localhost:8080/xmlui/handle/123456789/1542Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Reg.No:BR0120003 | - |
| dc.date.accessioned | 2023-12-11T08:25:43Z | - |
| dc.date.available | 2023-12-11T08:25:43Z | - |
| dc.date.issued | 2023 | - |
| dc.identifier.uri | http://localhost:8080/xmlui/handle/123456789/1542 | - |
| dc.description.abstract | Background and Objective: Prothrombotic coagulopathy is a characteristic feature of severe COVID-19 leading to multiorgan failure and death. Extensive pulmonary vascular microthrombi with relatively preserved lung compliance has been described to be a critical factor for refractory hypoxemia in severe COVID-19. This study is done to assess the effect of recombinant tissue plasminogen activator in severe COVID-19 patients associated with hypoxemia refractory to standard line of treatment. | en_US |
| dc.language.iso | en_US | en_US |
| dc.publisher | KLE Academy of Higher Education and Research, Belagavi | en_US |
| dc.title | Rescue therapy for severe covid-19associated Acute respiratory distress Syndrome with recombinant tissue Plasminogen activator (rtpa)- retrospective Observational study | en_US |
| dc.type | Dissertations | en_US |
| Appears in Collections: | Respiratory Medicine MD | |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| BR0120003.pdf | 4.36 MB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.